COMMUNIQUÉS West-GlobeNewswire

Avalyn Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis
01/04/2025
Topline data from the single- and multiple-ascending dose studies confirmed safety and favorable tolerability profile of AP02 at all dose levels Full safety, tolerability, and pharmacokinetics data to be presented at [...]
Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme
01/04/2025
CARLSBAD, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today they have entered a non-binding Memorandum of Understanding (MOU) to acquire Marizyme (OTC [...]
Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes
01/04/2025
DSMB supports advancement for Sernova’s clinical trial Study is on track to meet key clinical trial endpoints LONDON, Ontario and BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: [...]
NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disorders
01/04/2025
BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain [...]
Evaxion announces business update and full year 2024 financial results
01/04/2025
COPENHAGEN, Denmark, April 1, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces [...]
Context Therapeutics to Participate in Upcoming Investor Conferences
01/04/2025
PHILADELPHIA, April 01, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/04/2025
CLEVELAND, April 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved [...]
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
01/04/2025
TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of [...]
Kura Oncology to Participate in Stifel Targeted Oncology Forum
01/04/2025
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes
01/04/2025
Presentation Shows Pronounced Reduction in Key Plasma Biomarkers Among Prespecified Study Population PURCHASE, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) ( [...]
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
01/04/2025
Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations and promotion of Oliver Dolan to [...]
Best Cutting and Bulking SARMS for Muscle Growth and Fat Loss 2025 - Buy Legal SARMS Online from CrazyBulk
01/04/2025
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Looking to transform your physique with the best cutting and bulking SARMs available online in 2025? Selective Androgen Receptor Modulators (SARMs) have become the go-to [...]
Kraig Biocraft Laboratories Secures Four Registered Trademarks for SpydaSilk® Brand, to Advance Commercialization Strategy for Recombinant Spider Silk
01/04/2025
ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or the "Company"), a world leader in recombinant spider silk technology, today announced that it has [...]
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
01/04/2025
MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief [...]
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
01/04/2025
ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal [...]
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update
01/04/2025
Company continues to progress toward the signing of a definitive merger agreement with Renovaro PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a science-driven company leveraging its [...]
SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy
01/04/2025
Newly Appointed Board Chair, Philip Astley-Sparke, Brings Transatlantic Late-Stage Development, Regulatory and Commercial Expertise Strengthened Leadership and Expanded U.S. Presence Positions SynOx for Regulatory [...]
ITM Appoints Dr. Celine Wilke as Chief Medical Officer
01/04/2025
Experienced leader in radiopharmaceutical drug development, regulatory, and clinical strategies will advance ITM’s broad pipeline and clinical development strategy Garching / Munich, Germany, April 01, 2025 – ITM [...]
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
01/04/2025
ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro- [...]

Pages